

Rivaroxaban in Venous Thromboembolism (VTE)

Venous Thromboembolism (VTE)

Venous thromboembolism (VTE) is the most common, avoidable cause of hospital death¹.

- ◆ The worldwide incidence of VTE is 1 per 1000²
- ◆ In the EU, more than twice as many people die from VTE than from breast cancer, prostate cancer, AIDS and traffic accidents combined³

VTE encompasses two serious conditions:

Deep vein thrombosis (DVT) is a blood clot that forms in the veins that lie deep within the muscles, usually in the leg or pelvis. If all or part of the DVT breaks off and the blood clot moves to block a vessel in the lungs, it is known as a **pulmonary embolism (PE)**⁶, which can be rapidly fatal.

Deep vein thrombosis (DVT)

- ◆ Even in the absence of a PE, DVT alone can have burdensome and costly consequences such as post-thrombotic syndrome⁷
- ◆ The rate of VTE recurrence remains high, with hospital readmission for DVT at 19%⁸

Annual estimated incidence of DVT



Pulmonary embolism (PE)

- ◆ About 1 in 10 deaths that occur in the hospital is caused by pulmonary emboli¹⁰
- ◆ 10–25% of PEs are rapidly fatal¹¹, usually within 2 hours of the onset of symptoms¹². PE can recur, and if it does, it is usually fatal¹³

Annual estimated incidence of acute PE



VTE can be difficult to diagnose, so it is important people are aware of the signs and symptoms

Symptoms of DVT can include:

Pain, swelling, redness of the area usually the leg, and dilation of the surface veins; the skin may also be warm to the touch

Symptoms of PE can include:

Acute shortness of breath, chest pain, rapid heart rate and light headedness; some people may also cough blood

Who is at Risk of VTE?

- ◆ Patients undergoing major orthopaedic surgery for hip or knee replacement or major surgery for cancer
 - Without preventative treatment, the absolute DVT risk after hip or knee surgery is between 40% and 60%¹
- ◆ Patient-related, predisposing risk factors include inherited thrombophilia, advanced age, obesity, prior VTE and varicose veins¹
- ◆ Patients admitted to hospital for an acute medical condition

Economic burden

The complications associated with VTE and its treatment are frequent and costly. The main drivers of these VTE costs are initial and recurrent events requiring hospitalisation.

- ◆ In Europe, the annual cost of managing all-cause VTE has been estimated at approximately €4,000 per patient¹⁴



VTE Prevention and Treatment

Anticoagulants are the cornerstone of therapy for prevention and treatment of potentially deadly blood clots, but widely used older therapies are associated with significant drawbacks for the patient that challenge optimal treatment.

- ◆ The older therapy for **prevention of VTE** associated with orthopaedic surgery is a class of injectable anticoagulant drugs known as low molecular weight heparins (LMWH)
- ◆ The older therapy for **treatment of VTE and long-term prevention** is the complex dual-drug treatment of daily injections of LMWH followed by a transition to long-term oral therapy with a vitamin K antagonist (VKA), such as warfarin. As well as its complex dosing, the dual-drug treatment carries an increased risk of major bleeding¹⁵

Limitations of older VTE therapies may contribute to their under-utilisation¹⁶, creating challenges for patients and leaving them at risk.

Novel oral anticoagulants (OACs) can overcome the limitations of older anticoagulants to prevent and/or treat venous and arterial thromboembolic (VAT) conditions.

VTE Treatment and Prevention of Recurrence: For adult patients with DVT and PE, rivaroxaban was the first novel OAC approved for acute treatment and the prevention of recurrent VTE.

As the oral, single-drug treatment, rivaroxaban 15 mg twice daily offers fast and effective blood clot regression and protection from early recurrence in the first 21 days without the need for injections or routine coagulation monitoring^{17,18,19,20}. Then once-daily rivaroxaban 20 mg can provide enduring protection from the danger of DVT and/or PE recurrence²¹ for as long as treatment is needed. Furthermore, oral once-daily rivaroxaban offers patients greater convenience and satisfaction (compared to dual-drug treatment), supporting adherence and persistence that are critical for good patient outcomes²².

Single-Drug Approach

15 mg BID


After 3 weeks Transition to 20 mg OD

Additionally, rivaroxaban was shown to halve the risk of major bleeding in these patients compared with the dual-drug treatment of LMWH and VKA. Clinically relevant bleeding was comparable with dual-drug treatment^{15,23}.

ESC Guidelines on the diagnosis and management of acute PE (updated August 2014) recommend rivaroxaban as a treatment option for intermediate or low risk PE patients, as well as for extended treatment²⁴


VTE Prevention in Adult Patients Following Elective Hip or Knee Replacement Surgery:

For adult patients who have had hip or knee replacement surgery, one 10 mg tablet of rivaroxaban, once-daily provides superior protection against VTE with similar safety compared to the LMWH enoxaparin^{17,25,26,27}. In real-world settings, patients on rivaroxaban were also shown to experience fewer symptomatic VTEs and similar rates of major bleeding complications post-surgery compared to older treatments²⁸.



Rivaroxaban in Venous Thromboembolism (VTE) - Continued

Rivaroxaban VTE Regulatory Milestones



*UK's NICE issued Final Guidance in July 2012 recommending rivaroxaban for National Health Service (NHS) use for the treatment of DVT and the prevention of recurrent DVT and PE following an acute DVT in adults. In April 2013 NICE also issued Final Guidance recommending rivaroxaban for NHS use for the treatment of PE and the prevention of recurrent DVT and PE. The positive NICE appraisals were based on detailed analysis of the clinical and cost-effectiveness benefits of rivaroxaban^{29,30} **European Society of Cardiology (ESC) published updated Guidelines on the diagnosis and management of acute PE in August 2014 recommending rivaroxaban as a treatment option for patients with intermediate or low risk of PE, as well as for extended treatment²⁴

About Rivaroxaban

Rivaroxaban is the most broadly indicated and most prescribed novel OAC³¹ and is marketed under the brand name Xarelto®. Rivaroxaban is approved for five indications across seven distinct areas of use, protecting patients across more venous and arterial thromboembolic (VAT) conditions than any other novel OAC:



The prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors



The treatment of deep vein thrombosis (DVT) in adults



The treatment of pulmonary embolism (PE) in adults*



The prevention of recurrent DVT and PE in adults



The prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip replacement surgery



The prevention of VTE in adult patients undergoing elective knee replacement surgery



The prevention of atherothrombotic events (cardiovascular death, heart attack or stroke) after an acute coronary syndrome in adult patients with elevated cardiac biomarkers when co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine

Whilst licences may differ from country to country, across all indications rivaroxaban is approved in more than 125 countries. Rivaroxaban was discovered by Bayer HealthCare, and is being jointly developed with Janssen Research & Development, LLC. Rivaroxaban is marketed outside the U.S. by Bayer HealthCare and in the U.S. by Janssen Pharmaceuticals, Inc. (a Johnson & Johnson Company).

Anticoagulant medicines are potent therapies used to prevent or treat serious illnesses and potentially life threatening conditions. Before initiating therapy with anticoagulant medicines, physicians should carefully assess the benefit and risk for the individual patient. Responsible use of rivaroxaban is a very high priority for Bayer, and the company has developed a Prescribers Guide for physicians and a 'Xarelto' Patient Card for patients to support best practice.

To learn more, please visit <https://prescribe.xarelto.com>

To learn more about thrombosis, please visit www.thrombosisadviser.com

To learn more about VAT, please visit www.VATspace.com

To learn more about 'Xarelto', please visit www.xarelto.com

References:

- Geerts WH, Bergqvist D, Pineo GF, et al. Chest. 2008;133(6 Suppl):381S-453S
- Bramlage P, Pittrow D, & Kirch W. Eur J Clin Invest. 2005;35 Suppl 1,4-11
- Cohen AT, Agnelli G, Anderson FA, et al. Thromb Haemost. 2007;98(4):756-764
- Roger VL, Go AS, Lloyd-Jones DM, et al. Circulation. 2012;125(1):e2-e220
- Turpie AG. Thromboprophylaxis After Major Orthopaedic Surgery: State of the Art. European Instructional Lectures. 2009;9:29-38
- Patient UK. Deep vein thrombosis. Available at: <http://www.patient.co.uk/health/Deep-Vein-Thrombosis.htm> Accessed January 2015
- Kearon C. Circulation. 2003;107(23 Suppl 1):J22-I30
- Woodward T, Kachroo S, Bookhar BK, et al. Systematic review of the economic burden of venous thromboembolism treatment. Paper presented at ISPOR 15th Annual International Meeting; May 2010; Atlanta, GA. Abstract PCV60
- Coalition to Prevent VTE. Venous thromboembolism: prevention and treatment background. Available at: http://www.coalitiontopreventvte.org/INDEX_CFM/THE_BURDEN_OF_VTE/VID/DCD0A03F_1422_16B3_78E0B9EB0571.HTM Accessed January 2015
- Geerts WH, Pineo GF, Bergqvist D et al. Chest. 2004; 126(3 Suppl): 338S-400S
- Heit JA. J Thromb Thrombolysis. 2006;21(1):23-29
- Anderson F, Audet AM. Preventing Deep Vein Thrombosis and Pulmonary Embolism: A Practical Guide to Evaluation and Improvement. Center for Outcomes Research, UMass Medical School. 1998. Available at: http://www.outcomes-umassmed.org/DVT/best_practice/ Accessed January 2015
- Nijkeuter M, Söhne M, Tick L et al. Chest. 2007; 131(2) 517-523
- Haas S & Lassen MR. Venous thromboembolism after elective hip and knee replacement surgery. European Journal of Hospital Pharmacy Practice. EJHP Practice 2010;17-19
- Prins M.H., Lensing A.W.A., Bauersachs R., et al. Thrombosis J. 2013;11(1):21
- Lip GY & Lim HS. Lancet Neurol. 2007;6(11):981-993
- Xarelto Summary of Product Characteristics as approved by the European Commission
- Warfarin Summary of Product Characteristics as approved by the European Commission
- Clexane (enoxaparin) Summary of Product Characteristics as approved by the European Commission
- Limone B.L., Hernandez A.V., Michalak D., et al. Thromb Res. 2013;132(4):420-425
- The EINSTEIN Investigators. N Eng J Med. 2010;363:2499-2510
- Bamber L., Wang M.Y., Prins M.H., et al. Thromb Haemost. 2013;110:732-741
- The EINSTEIN-PE Investigators. N Eng J Med. 2012;366:1287-1297
- Konstantinides SV, Torbicki A, Agnelli G, et al. Euro Heart J. doi:10.1093/eurheartj/ehu283
- Eriksson BI, Borris LC, Friedman RJ, et al. RECORD1. N Eng J Med. 2008;358:2765-2775
- Kakkar AK, Brenner B, Dahl OE, et al. RECORD2. Lancet. 2008;372:31-9
- Lassen MR, Ageno W, Borris LC, et al. RECORD3. N Engl J Med. 2008;385:2766-2786
- Turpie AG, Haas S, Kreuzer R, et al. XAMOS; Thromb Haemost. 2014;111(1):94-102
- National Institute for Health and Care Excellence (NICE). Final appraisal determination. Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism. Available at: <http://publications.nice.org.uk/rivaroxaban-for-the-treatment-of-deepvein-thrombosis-and-prevention-of-recurrent-deep-vein-ta261> Accessed January 2015
- National Institute for Health and Care Excellence (NICE). Final appraisal determination. Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism. Available at: <http://www.nice.org.uk/guidance/TA287/chapter/1-Guidance> Accessed January 2015
- IMS Health MIDAS, Database: Monthly Sales January 2015 *Rivaroxaban is not recommended as an alternative to unfractionated heparin in patients with PE who present hemodynamic instability or who may receive thrombolysis or pulmonary embolectomy